PT - JOURNAL ARTICLE AU - Monod, Mélodie AU - Brizzi, Andrea AU - Galiwango, Ronald M AU - Ssekubugu, Robert AU - Chen, Yu AU - Xi, Xiaoyue AU - Kankaka, Edward Nelson AU - Ssempijja, Victor AU - Dörner, Lucie Abeler AU - Akullian, Adam AU - Blenkinsop, Alexandra AU - Bonsall, David AU - Chang, Larry W AU - Dan, Shozen AU - Fraser, Christophe AU - Golubchik, Tanya AU - Gray, Ronald H AU - Hall, Matthew AU - Jackson, Jade C AU - Kigozi, Godfrey AU - Laeyendecker, Oliver AU - Mills, Lisa A. AU - Quinn, Thomas C AU - Reynolds, Steven J. AU - Santelli, John AU - Sewankambo, Nelson K. AU - Spencer, Simon EF AU - Ssekasanvu, Joseph AU - Thomson, Laura AU - Wawer, Maria J AU - Serwadda, David AU - Godfrey-Faussett, Peter AU - Kagaayi, Joseph AU - Grabowski, M Kate AU - Ratmann, Oliver AU - Rakai Health Sciences Program AU - PANGEA-HIV consortium TI - Longitudinal population-level HIV epidemiologic and genomic surveillance highlights growing gender disparity of HIV transmission in Uganda AID - 10.1101/2023.03.16.23287351 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.16.23287351 4099 - http://medrxiv.org/content/early/2023/11/13/2023.03.16.23287351.short 4100 - http://medrxiv.org/content/early/2023/11/13/2023.03.16.23287351.full AB - HIV incidence in eastern and southern Africa has historically been concentrated among girls and women aged 15-24 years. As new cases decline with HIV interventions, population-level infection dynamics may shift by age and gender. Here, we integrated population-based surveillance of 38,749 participants in the Rakai Community Cohort Study and longitudinal deep sequence viral phylogenetics to assess how HIV incidence and population groups driving transmission have changed from 2003 to 2018 in Uganda. We observed 1,117 individuals in the incidence cohort and 1,978 individuals in the transmission cohort. HIV viral suppression increased more rapidly in women than men, however incidence declined more slowly in women than men. We found that age-specific transmission flows shifted, while HIV transmission to girls and women (aged 15-24 years) from older men declined by about one third, transmission to women (aged 25-34 years) from men that were 0-6 years older increased by half in 2003 to 2018. Based on changes in transmission flows, we estimated that closing the gender gap in viral suppression could have reduced HIV incidence in women by half in 2018. This study suggests that HIV programs to increase HIV suppression in men are critical to reduce incidence in women, close gender gaps in infection burden and improve men’s health in Africa.Competing Interest StatementDr. Wawer and Dr. Gray are paid consultants to the Rakai Health Sciences Program and serves on its Board of Directors. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.Funding StatementThis study was supported by the Bill & Melinda Gates Foundation (OPP1175094 to CF, OPP1084362 to Prof Deenan Pillay); the National Institute of Allergy and Infectious Diseases (U01AI051171 to RHG, U01AI075115 to RHG, UM1AI069530-16 to Dr Mary Glenn Fowler, Dr Philippa Musoke, and Dr Aaron Tobian, R01AI087409 to RHG, U01AI100031 to RHG, R01AI110324 to RHG, R01AI114438 to MJW, K25AI114461 to Dr Xiangrong Kong, R01AI123002 to Dr Cindy Liu, K01AI125086 to MKG, R01AI128779 to Dr Aaron Tobian, R01AI143333 to LWC, R21AI145682 to Dr Caitlin Kennedy, R01AI155080 to MKG, ZIAAI001040 to TCQ); the National Institute of Mental Health (F31MH095649 to Dr Jennifer Wagman, R01MH099733 to Ned Sacktor and MJW, R01MH107275 to LWC, R01MH115799 to MJW and LWC, U19MH110001 to Dr Mary McKay and Dr Fred Ssewamala); the National Institute of Child Health and Development (R01HD038883 to RHG, R01HD050180 to MJW, R01HD070769 to MJW, R01HD091003 to JSa); the Division of Intramural Research of the National Institute for Allergy and Infectious Diseases (TCQ, OL and SJR); NIAID K01AA024068 to Dr Jennifer Wagman; the National Heart, Lung, and Blood Institute (R01HL152813 to LWC); the Fogarty International Center (D43TW009578 to RHG, D43TW010557 to LWC); the Doris Duke Charitable Foundation to Dr Aaron Tobian; the Johns Hopkins University Center for AIDS Research (P30AI094189 to Dr Richard Chaisson); the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (NU2GGH000817 to RHSP); the Engineering and Physical Sciences Research Council through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford (EP/S023151/1 to Prof Axel Gandy); and the Imperial College London President's PhD Scholarship fund to YC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was independently reviewed and approved by the Ugandan Virus Research Institute, Scientific Research and Ethics Committee, protocol GC/127/13/01/16; the Ugandan National Council of Science and Technology; and the Western Institutional Review Board, protocol 200313317. All study participants provided written informed consent at baseline and follow-up visits using institutional review board approved forms. This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes